Soy isoflavone consumption and colorectal cancer risk: a systematic review and meta-analysis

Yi Yu, Xiaoli Jing, Hui Li, Xiang Zhao & Dongping Wang

Colorectal cancer (CRC) is one of the most predominant solid carcinomas in Western countries. However, there is conflicting information on the effects of soy isoflavone on CRC risk. Therefore, we performed a meta-analysis to assess the association between soy isoflavone consumption and CRC risk in humans using PubMed, Embase, Web of Science, and Cochrane Library databases. A total of 17 epidemiologic studies, which consisted of thirteen case-control and four prospective cohort studies, met the inclusion criteria. Our research findings revealed that soy isoflavone consumption reduced CRC risk (relative risk, RR: 0.78, 95% CI: 0.72–0.85; \( I^2 = 34.1\% \), \( P = 0.024 \)). Based on subgroup analyses, a significant protective effect was observed with soy foods/products (RR: 0.79; 95% CI: 0.69–0.89), in Asian populations (RR: 0.79; 95% CI: 0.72–0.87), and in case-control studies (RR: 0.76; 95% CI: 0.68–0.84). Therefore, soy isoflavone consumption was significantly associated with a reduced risk of CRC risk, particularly with soy foods/products, in Asian populations, and in case-control studies. However, due to the limited number of studies, other factors may affect this association.

Colorectal cancer (CRC) is the third most prevalent cancer worldwide and one of the most common solid carcinomas in Western countries\(^1\). Therefore, primary CRC prevention efforts should be explored. Based on recent estimates, the CRC incidence rate is higher in developed nations than in developing countries\(^2\). Lifestyle habits and diet may play key roles in the etiology of CRC\(^3,4\). Soy isoflavones, which are phytoestrogens, have a protective effect against cancer formation and susceptibility to radiotherapy; other anti-cancer phytochemicals in soy beans include phenolic acids, plant sterol, and protease inhibitors\(^5–10\).

The association between soy isoflavone consumption and CRC risk has been evaluated\(^11,12\). A meta-analysis of four cohort studies and seven case-control studies failed to detect any association between soy consumption and risk of CRC, colon cancer, or rectal cancer\(^12\). Due to a low statistical power and small sample size of each individual study, the results were not consistent with the findings of several epidemiological studies\(^13–16\). Therefore, the objective of this meta-analysis was to assess the association between soy isoflavone consumption and CRC risk. Our meta-analysis included case-control and cohort studies\(^13–29\) and subgroup analyses by geographical area, study type, anatomical subsite, gender, and soy food type.

Methods

Search strategy. We performed a literature search of relevant studies published through November, 2015 using PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), Embase (http://www.embase.com/), Web of Science (http://wokinfo.com/), and Cochrane Library (http://www.thecochranelibrary.com/). The search strategy included terms for outcome (colorectal neoplasm, colorectal cancer, colon cancer, and rectal cancer) and exposure (soy, soy foods/products, isoflavones, soybeans, flavonoid, tofu, soy protein, miso, genistein, phytoestrogen, and natto). We designed, implemented, and reported our meta-analysis based on epidemiological study guidelines\(^30\). In addition, we reviewed the reference lists from all relevant articles to identify additional studies. A search for unpublished literature was not performed.

Study selection. The study inclusion criteria were the following, (i) studies written in English with case-control or cohort design; (ii) original human clinical trials that evaluated the association between soy isoflavone consumption and CRC risk.
isoﬂavone consumption and CRC risk; and (iii) use of risk point estimates, e.g., odd ratio (OR), relative risk (RR), or hazard ratio (HR) estimates with 95% conﬁdence intervals (CIs).

Data extraction. The extracted data were the ﬁrst author’s name, year of publication, cancer type, population and country, total number of cases, dietary assessment method, estimates of soy isoﬂavone intake, and RRs or ORs with 95% CIs. Five publications reported separate RRs for soy foods and soy isoﬂavones, ﬁve publications reported separate RRs for male and female participants, and two publications reported separate RRs for colon and rectal cancers. In these cases, RRs were extracted individually.

Statistical analysis. We assessed the association between soy isoﬂavone consumption and CRC risk using the reported RRs. Soy isoﬂavones were deﬁned as soy foods, soy products, isoﬂavones, tofu, soy milk, miso, natto, genistein, daidzein, and isoﬂavonoids. When adjusted and crude RRs were provided, the most adjusted RRs were extracted.

We used HR and OR to evaluate CRC risk. HR and OR were considered to be approximations to RR, because CRC is a rare outcome in humans. Pooled RRs and 95% CIs were estimated on the basis of the most adjusted RRs or ORs for the highest versus lowest soy isoﬂavone intake.

We used F and Q statistics to assess possible homogeneity of RRs across studies, which is a quantitative measure of inconsistency among studies31. Pooled ORs and 95% CIs were calculated using a random effects model32. To estimate cancer site-speciﬁc and ethnicity-speciﬁc effects, subgroup analyses were performed by geographic area, study type, anatomical subsite, gender, and soy isoﬂavone type. Additionally, a sensitivity analysis was conducted to investigate the effect of a single study on the overall risk estimate. This allowed us to estimate whether the results could have been signiﬁcantly affected by a single study.

Data analyses were performed with STATA version 13.0. Statistical signiﬁcance was set at P ≤ 0.05. Egger’s and Begger’s regression models were used to evaluate potential publication bias31. All reported P values were from two-sided statistical tests.

Results
The study selection process is graphically described in Fig. 1. Twenty studies met our inclusion criteria. Two studies were subsequently excluded, because one was an ecological study and the other study failed to report RR or 95% CI. After conducting a sensitivity analysis, we excluded the Ravasco et al. study33 (Fig. 2). Finally, 17 studies13–29 were included in the meta-analysis (Table 1). The most predominant dietary assessment method used in these studies was the food frequency questionnaire (FFQ).

Thirteen studies assessed the association between soy product consumption and CRC risk, while nine studies evaluated the association between isoﬂavone consumption and CRC risk. Among them, six studies separately presented ﬁndings for men and women, and two studies separately reported results for risk of rectal and colon cancers. Twelve studies were conducted in Asia and ﬁve in non-Asia countries (Table 2). Data from both men and women were individually extracted. Different soy food types were evaluated in these studies; some studies assessed more than one type of soy food. Therefore, we used the risk estimate that was the most representative of overall soy consumption and the soy food item that was the most commonly consumed. In descending order, the most common soy food or products were tofu (bean curd), soy beans, soy milk, and miso soup (soy paste soup).

The analysis of the 17 studies yielded a combined risk estimate of 0.77 (95% CI, 0.72–0.82; P = 0.024) with a heterogeneity value (P) of 34.1% (Fig. 3). However, the results from the 17 studies were inconsistent. Nine studies reported that soy isoﬂavone intake was associated with a signiﬁcant reduction in CRC risk, whereas other studies reported no association. Six studies reported that soy isoﬂavone intake was associated with a signiﬁcant reduction in CRC risk in both men and women, three studies reported a signiﬁcant reduction in CRC risk only in women, and other studies reported no association in women or men. We conducted a sensitivity analysis (Fig. 4) and meta regulation test (Fig. 5). The sensitivity analysis revealed that the publication dates were similar. The geographical
area was associated with ~44.3% heterogeneity reduction across the studies. No publication bias was detected (Figs 6 and 7) based on Egger’s and Begger’s regression models.

Because there were differences in study types (cohort or case-control), study populations (Asian or non-Asian), anatomical subsite (colorectal, colon, or rectum), gender (female versus male), and soy isoflavone type (soy foods/products or soy isoflavones) among the studies, we further conducted subgroup analyses to determine the effect of these factors in our analyses (Table 2). We obtained a statistically significant protective effect of soy foods/products (RR: 0.79; 95% CI: 0.72–0.84), in Asian populations (RR: 0.79; 95% CI: 0.73–0.85), and with case-control studies (RR: 0.76; 95% CI: 0.70–0.81).

Discussion
We analyzed 17 epidemiological studies that assessed the association between soy isoflavone consumption and CRC risk in humans. The findings revealed that the consumption of soy isoflavones was associated with a 23% reduction in CRC risk. CRC is caused by environmental (e.g., diet and lifestyle) and genetic factors. When stratified by geographical area, a significant protective effect of soy isoflavone consumption was observed in Asian populations, which are likely to be attributed to their lifestyle habits and overall health. Ecological and immigration studies have shown that differences in CRC risk among populations are largely attributed to environmental factors, such as eating habits. Asian populations have higher intakes of soy isoflavones than Western populations. The consumption of Western diets, which are high in fat and calories, is associated with an increased incidence in CRC. Dietary fat increases the secretion of bile acids, which directly damage the intestinal mucosa, stimulate epithelial hyperplasia, and increase CRC risk. On the other hand, the frequency of physical activity is lower in Asian populations than in American or European populations. Regular physical activity is a protective factor against CRC, because it reduces random motions of the intestine and stimulates bowel movements. Additionally, physical activity promotes the secretion of prostaglandins, which stimulate peristalsis and cleansing and reduce the contact time between the intestinal mucosa and carcinogens. When stratified by study design, a significant protective effect of soy isoflavone intake was observed with case-control studies, which could be attributed to higher recall rates and greater selection bias in these types of studies. When stratified by soy foods/products and soy isoflavones, a significant protective effect was observed with soy foods/products, probably due to a limited number of studies focused on soy isoflavones.

Epidemiological and animal studies have found that the consumption of dietary soy decreases the incidence of certain tumors, including those of the colon and rectum. The three main soy isoflavone aglycones are genistein, daidzein, and glycitein. The mechanism by which soy protects against the development of CRC remains unclear. It has been reported that in CRC, there is a reduced expression of estrogen receptor-β (ER-β) expression. Dietary isoflavones increase ER-β expression, but reduce ER-α expression in the colon of female rats. In CRC patients, ER gene expression is either diminished or absent.

Our meta-analysis had some limitations. First, only studies written in English were included. Second, most studies used FFQs as the main dietary assessment method. Recall bias may have affected the results. Additionally, it was challenging to predict the effect of misclassification of case-control studies on the results. Third, certain confounding factors were not adjusted in the evaluated studies, e.g., family history of CRC, smoking, and alcohol consumption, which are important risk factors of CRC. Fourth, we failed to evaluate a dose-response relationship between soy isoflavone consumption and CRC risk.

There was heterogeneity across the studies in terms of soy isoflavone consumption, which is not surprising considering the differences in the study designs, soy types, and gender. Additionally, differences in geographic
| Study          | Year | Cancer type | Population and country | No. of cases | Dietary assessment | Exposure                   | Consumption comparison | Adjustment RR (95% CI) | Adjustment                                                                 |
|---------------|------|-------------|------------------------|--------------|--------------------|----------------------------|------------------------|------------------------|-----------------------------------------------------------------------------|
| Aesun et al.  | 2015 | CRC         | 2,669 Korea            | 901          | SQFFQ              | Soy products               | Highest versus lowest   | Colorectal 0.67 (0.49–0.92), M 0.62 (0.39–1.00), F | Age, education, alcohol consumption, and regular physical activity |
| Raul et al.   | 2013 | CRC         | 825 Spain              | 424          | FFQ                | Isoflavones                | Highest versus lowest   | Colorectal 0.59 (0.35–0.99) | Sex, age, BMI, energy intake, alcohol and fiber intake                      |
| Budhathoki et al. | 2010 | CRC         | 1,631 Japan            | 816          | FFQ                | Soy foods                  | 37.2 (23.0–54.9) (mg/d) versus 35.5 (22.3–52.3) (mg/d) | Colorectal 0.65 (0.41–1.03), M 0.60 (0.29–1.25), F | Age, resident area, parental colorectal cancer, smoking, alcohol consumption, BMI, job, leisure time physical activity, and energy-adjusted intakes of calcium and n-3 polyunsaturated fatty acids |
| Ramadas et al.| 2009 | CRC         | 108 Malaysia           | 59           | FFQ                | Soy products               | <3 times/week versus ≥3 times/week | Colorectal 0.38 (0.15–0.98) | Age, ethnicity, gender, physical activity, height, BMI, waist circumference, energy intake, current alcohol consumption and smoking habits |
| Yang et al.   | 2009 | CRC         | 68,412 women China     | 321          | FFQ                | Soy foods                  | ≤12.8 versus > 21.0 g/d | Colorectal 0.67 (0.49–0.90), F | Birth calendar year, education, BMI, household income, physical activity, colorectal cancer in first-degree relatives, menopausal status, and dietary intakes of total calories, red meat, total fruit and vegetables, non-soy fiber, non-soy calcium, and non-soy folic acid |
| Wang et al.   | 2009 | CRC         | 38,408 women US        | 301          | SFFQ               | Soy foods (Tofu)           | <1 time/month versus ≥1 time/week | Colorectal 0.54 (0.20–1.46), F | Age, race, total energy intake, and randomized treatment assignment, BMI, smoking, alcohol consumption, physical activity, postmenopausal status, hormone replacement therapy use, multivitamin intake, family history of cancer in a parent or sibling, and intake of fruit and vegetables, fiber, folate, and saturated fat |
| Akhter et al. | 2008 | CRC         | 38,408 women Japan     | 886          | FFQ                | Soy foods                  | ≤35.4 versus > 169.9 g/d, M ≤35.6 versus >170.3 g/d, F | Colorectal 0.89 (0.68–1.17), M 1.04 (0.76–1.42), F | Age, public health center, area, history of diabetes mellitus, BMI, leisure time physical activity, cigarette smoking, alcohol drinking, energy intake, menopausal status, use of female hormones |

Continued
area may have contributed to the heterogeneity results; most of the studies were conducted in Asia, where the consumption of soy is high. Moreover, while some studies were adjusted for age, gender, and family history of CRC in the calculation of risk estimates, not all parameters were considered. The measurement units varied among the studies. Sensitivity analysis was performed by sequentially omitting one single study to assess the effect of each study on the overall results (Fig. 2). The Egger’s funnel plot revealed a P value > 0.05; the shape

### Table 1. Characteristics of the studies included in the meta-analysis.

| Study            | Year  | Cancer type | Population and country | No. of cases | Dietary assessment | Exposure | Consumption comparison | Adjustment RR (95% CI) | Adjustment | Notes                                                                 |
|------------------|-------|-------------|-------------------------|--------------|--------------------|----------|------------------------|------------------------|-------------|-----------------------------------------------------------------------|
| Oba et al.       | 2007  | Colon cancer| 30,221 Japan            | 213          | FFQ                | Soy products | ≤9.1 versus > 50.4 mg/d, M | 0.89 (0.67–1.17), M 1.07 (0.78–1.47), F | Age, physical activity, cigarette smoking status, height, BMI, alcohol and coffee consumption, hormone replacement therapy (for women) |
|                  |       |             |                         |              |                    | Isoflavones | ≤49.22 versus > 141.09 mg/d, M | Colon 1.24 (0.77–2.00), M 0.56 (0.34–0.92), F |             |                                                                 |
| Cotterchio et al.| 2006  | CRC         | 1,890 Canada            | 1,095        | FFQ                | Isoflavones | 0 versus >1.097 mg/d | 0.71 (0.58–0.86) | Age, sex, and total energy intake                                       |
| Rossi et al.     | 2006  | CRC         | 4,154 Italy             | 1,953        | FFQ                | Isoflavones | ≤14.4 versus >33.9 μg/d | 0.76 (0.63–0.91) | Age, sex, study center, family history of colorectal cancer, education, alcohol consumption, BMI, occupational physical activity, and energy intake |
| Huang et al.     | 2004  | CRC         | 50,706 Japan            | 1,352        | FFQ                | Bean curd | <3 versus >3 times/week | Colorectal 1.11 (0.92–1.33) | Age and sex |                                                                 |
| Nishi et al.     | 1997  | Colon Cancer| 660 Japan               | 330          | FFQ                | Soy products (Tofu) | <3 versus >3 times/week | Colorectal 0.79 (0.55–1.13), Rectum 1.02 (0.67–1.53) | Age, sex and registered residence |
|                  |       | Rectal cancer|                         |              |                    | Tofu      | 0 versus ≥25 g/d       | Colorectal 1.0 (0.6–1.6), M 0.9 (0.5–1.5), F | Nutrient intakes for calories, age, family history of colorectal cancer, alcoholic drink, cigarette smoking, Quetelet index previous five year, total calories, egg intake, lifetime recreational activity (in hours), and calcium intake |
| Le Marchan et al.| 1997  | CRC         | 1,192 US                | 1,192        | FFQ                | Tofu      | None versus ≥1 serving/week | Colorectal 0.55 (0.27–1.11) | Race; body mass index; vigorous leisure time activity; smoking; dietary fiber, folate, beta-carotene, and vitamin C |
| Witt et al.      | 1996  | CRC         | 488 US                  | 488          | FFQ                | Tofu or Soy beans | None versus ≥1 serving/week | Colorectal 1.0 (0.6–1.6), M 0.9 (0.5–1.5), F | Age, sex, age for colorectal cancer, prevalent disease, and BMI |
| Inoue et al.     | 1995  | Rectal Cancer| 31,782 Japan            | 432          | FFQ                | Bean curd | ≤3 versus >3 times/week | Proximal colon 0.9 (0.5–1.6), F Distal colon 1.3 (0.7–2.4), M 0.6 (0.4–1.0), F Rectum 1.2 (0.8–1.7), M 0.9 (0.6–1.5), F | Age |
| Hoshiyama et al. | 1993  | Colon Cancer| 653 Japan               | 181          | FFQ                | Soy bean  | ≤4 versus ≥8 times/week | Colon 0.6 (0.3–1.3), Rectum 0.4 (0.2–1.0) | Sex, age for colon cancer, selected food items; sex and age for rectal cancer |
| Kono et al.      | 1993  | Colon Cancer| 1,557 Japan             | 187          | FFQ                | Soy paste soup | <1 versus ≥2 bowls/d | Colorectal 0.87 (0.55–1.37) | Smoking, alcohol consumption, rank and BMI |

BMI: body mass index, CI: confidence interval, FFQ: food frequency questionnaire, RR: relative risk, SQFFQ: semi-quantitative food frequency questionnaire; F: female, M: male, Null: not provided.
of the Begger's funnel plot seemed symmetrical. There was no significant evidence for publication bias in our meta-analysis (P > 0.05).

In summary, our meta-analysis provided an updated and comprehensive evaluation of the association between soy isoflavone consumption and CRC risk, with an RR value of 0.77 (95% CI: 0.72–0.82, P = 0.024) and an I² value of 34.1%. A statistically significant protective effect was observed with soy foods/products (RR: 0.79; 95% CI: 0.72–0.84), in Asian populations (RR: 0.79; 95% CI: 0.73–0.85), and with case-control study designs (RR: 0.76;
Figure 4. Sensitivity analysis of soy isoflavone consumption and risk of colorectal cancer.

Figure 5. Meta regulation of isoflavone consumption and risk of colorectal cancer.

Figure 6. Egger’s funnel plot assessing publication bias among the studies.
95% CI: 0.70–0.81). Soy isoflavones play an important protective role in the pathogenesis of CRC, by a mechanism that remains to be elucidated. More cohort and intervention studies are required.

References
1. Stintzing, S. Management of colorectal cancer. F1000Prime Rep 6, 108 (2014).
2. Jamal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69–90 (2011).
3. Doyle, V. C. Nutrition and colorectal cancer risk: a literature review. Gastroenterol Nurs 30, 178–182 (2007).
4. Vargas, A. I. & Thompson, P. A. Diet and nutrient factors in colorectal cancer risk. Nutr Clin Prac 27, 613–623 (2012).
5. Pudenz, M., Roth, K. & Gerhauser, C. Impact of soy isoflavones on the epigenome in cancer prevention. Nutrients 6, 4218–4272 (2014).
6. Wu, A. H., Lee, E. & Vigen, C. Soy isoflavones and breast cancer. Am Soc Clin Oncol Educ Book 33, 102–106 (2013).
7. Andres, S., Abraham, K., Appel, K. E. & Lampen, A. Risks and benefits of dietary isoflavones for cancer. Crit Rev Toxicol 41, 463–506 (2011).
8. Hillman, G. G. & Singh-Gupta, V. Soy isoflavones sensitize cancer cells to radiotherapy. Free Radiat Biol Med 51, 289–298 (2011).
9. Messina, M. & Bennyink M. Soyfoods, isoflavones and risk of colon cancer: a review of the in vitro and in vivo data. Baillieres Clin Endocrinol Metab 12, 707–728 (1998).
10. Setchell, K. D. & Cole, S. J. Variations in isoflavone levels in soy foods and soy protein isolates and issues related to isoflavone databases and food labeling. J Agric Food Chem 51, 4146–4155 (2003).
11. Nordmann, A. J., Kasenda, B. & Briel, M. Meta-analyses: what they can and cannot do. BMJ 319, 1451–1455 (1999).
12. Begger’s funnel plot assessing publication bias among the studies.

Figure 7. Begger’s funnel plot assessing publication bias among the studies.

13. Nordmann, A. J., Kasenda, B. & Briel, M. Meta-analyses: what they can and cannot do.
14. Rossi, M. Cotterchio M.
15. Zamora-Ros, R. Budhathoki, S.
16. Le Marchand, L.
17. Huang, X. E.
18. Akhter, M.
19. Wang, L.
20. Oba, S.
21. Jemal, A.
22. Witte, J. S.
23. Nishi, M., Yoshida, K., Hirata, K. & Miyake, H. Eating habits and colorectal cancer.
24. Witte, J. S.
25. Inoue, M.
26. Hoshiyama, Y., Sekine, T. & Sasaba, T. A case-control study of colorectal cancer and its relation to diet, cigarettes, and alcohol consumption in Saitama Prefecture, Japan. Tohoku J Exp Med 171, 153–165 (1993).
27. Kono, S., Imanishi, K., Shinchi, K. & Yanai, P. Relationship of diet to small and large adenomas of the sigmoid colon. Jpn J Cancer Res 84, 13–19 (1993).
28. Cotterchio, M. et al. Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. J Nutr 136, 3046–3053 (2006).
29. Ross, M. et al. Flavonoids and colorectal cancer in Italy. Cancer Epidemiol Biomarkers Prev 15, 1555–1558 (2006).
30. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557–560 (2003).
31. Beg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101 (1994).
32. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 45, 139–145 (2015).
33. Ravasco, P., Monteiro-Grillo, I., Marqués Vidal, P. & Camilo, M. E. Nutritional risks and colorectal cancer in a Portuguese population. Nutr Hosp 20, 165–172 (2005).
34. Tárraga López, P. J., Albero, J. S. & Rodríguez-Montes, J. A. Primary and Secondary Prevention of Colorectal Cancer. *Clin Med Insights Gastroenterol* 7, 33–46 (2014).
35. Yamamoto, S. et al. Soy, isoflavones, and breast cancer risk in Japan. *J Natl Cancer Inst* 95, 906–913 (2003).
36. Bernstein, C. et al. A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies. *Cancer Res* 59, 2355–2357 (1999).
37. Simmen, F. A. & Simmen, R. C. The maternal womb: a novel target for cancer prevention in the era of the obesity pandemic? *Eur J Cancer Prev* 20, 539–548 (2011).
38. Larsson, S. C., Rutegård, J., Bergkvist, L. & Wolk, A. Physical activity, obesity, and risk of colon and rectal cancer in a cohort of Swedish men. *Eur J Cancer* 42, 2590–2597 (2006).
39. Papenburg, R., Bounous, G., Fleiszer, D. & Gold, P. Dietary milk proteins inhibit the development of dimethylhydrazine-induced malignancy. *Tumour Biol* 11, 129–136 (1990).
40. Toyomura, K. & Kono, S. Soybeans, soy foods, isoflavones and risk of colorectal cancer: a review of experimental and epidemiological data. *Asian Pac J Cancer Prev* 3, 125–132 (2002).
41. Spector, D., Anthony, M., Alexander, D. & Arab, L. Soy consumption and colorectal cancer. *Nutr Cancer* 47, 1–12 (2003).
42. Hakkak, R., Korourian, S., Ronis, M. J., Johnston, J. M. & Badger, T. M. Soy protein isolate consumption protects against azoxymethane-induced colon tumors in male rats. *Cancer Lett* 166, 27–32 (2001).
43. Thiagarajan, D. G., Bennink, M. R., Bourquin, L. D. & Kavas, E. A. Prevention of precancerous colonic lesions in rats by soy flakes, soy flour, genistein, and calcium. *Am J Clin Nutr* 68, 1394S–1399S (1998).
44. Bielecki, A., Roberts, J., Mehta, R. & Raju, J. Estrogen receptor-β mediates the inhibition of DLD-1 human colon adenocarcinoma cells by soy isoflavones. *Nutr Cancer* 63, 139–150 (2011).
45. Kramer, F., Johnson, I. T., Doleman, J. F. & Lund, E. K. A comparison of the effects of soya isoflavonoids and fish oil on cell proliferation, apoptosis and the expression of oestrogen receptors alpha and beta in the mammary gland and colon of the rat. *Br J Nutr* 102, 29–36 (2009).
46. Issa, J. P. et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. *Nat Genet* 7, 536–540 (1994).
47. Imperiale, T. F. & Ransohoff, D. F. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review. *Ann Intern Med* 156, 703–709 (2012).
48. Rustgi, A. K. The genetics of hereditary colon cancer. *Genes Dev* 21, 2525–2538 (2007).
49. Shin, A. et al. Associations of cigarette smoking and alcohol consumption with advanced or multiple colorectal adenoma risks: a colonoscopy-based case-control study in Korea. *Am J Epidemiol* 174, 552–562 (2011).

**Acknowledgements**

This study was supported by grants from the National Natural Science Foundation of China (NSFC-2013-81372022), and Guangdong Natural Science Foundation (2011B061300031).

**Author Contributions**

Y.Y., X.J. and H.L. wrote the main manuscript text and X.Z. and D.W. prepared Figs 1–7. All authors reviewed the manuscript. Y.Y., X.J. and H.L. contributed equally to this work.

**Additional Information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Yu, Y. et al. Soy isoflavone consumption and colorectal cancer risk: a systematic review and meta-analysis. *Sci. Rep.* 6, 25939; doi: 10.1038/srep25939 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/